Novartis has appointed the new technical member Dr P C Chakraborti and to review the case before the Intellectual Property Appellate Board (IPAB).  The Supreme Court has directed the IPAB to list the matter for hearing on 3rd November to decide further course of action. 

The Honourable Court has further directed the IPAB to hear the matter on a day-to-day basis. The Supreme Court held that a new technical member has to be appointed to the Intellectual Property Appellate Board to consider the Novartis appeal against the rejection of the Glivec beta patent by the Indian Patent Office. Natco was the only party to disagree with the Government of India’s proposal to have a two-member IPAB panel to hear the case. The IPAB hearing on the denial of a patent for Glivec (imatinib mesylate) beta form was delayed pending the Court's decision on the Natco petition. Nevertheless, we have confidence in the Indian legal system.

Glivec, Nocartis’s life-saving breakthrough drug for cancer, has been granted a patent in nearly 40 countries – including China, Russia, Taiwan and all major Western countries.